Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.
Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.
Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.
Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.
Microgravity should not be a destination for pharmaceutical R&D, but another experimental environment.
Editor's Picks
